Newborn Screening for Sickle Cell Disease and other Haemoglobinopathies – MDPI – 2019
This Special Issue related to newborn screening for Sickle Cell Disease and other Haemoglobinopathies tried to cover the most widely faced challenges in the field of newborn screening for SCD: unmet needs in Europe and healthcare policy implementation as well as patient involvement and development of new diagnostic techniques.
- Sickle Cell Disease (SCD) is among the most common genetic disorders in the world, affecting over 300,000 newborns annually, with estimates for further increases to over 400,000 annual births within the next generation and with a wider geographical distribution of affected individuals due to global migration.
- Both the World Health Organization (WHO) and the United Nations have identified SCD as a current global health burden.
- Global diseases can be tackled only with global and coordinated efforts of different experts ranging from clinicians to technicians and basic scientists, as well as healthcare planners and the patients themselves across different countries. This Special Issue brings together a multidisciplinary global team presenting the actual situation and proposals for future developments.
Test associated with this resource
Related instrument
A high-throughput Capillary Electrophoresis solution for newborn screening of hemoglobin disorders.
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country. Please contact your local Sebia representative. Information intended for healthcare professionals. Carefully read the instructions in the reagent package inserts and instrument manuals.